Choosing the tumoral epilepsy surgery candidate

Area of Science:

• Neuro-oncology
• Neurosurgery
• Epileptology

Background:

• Epilepsy is a common and often drug-resistant complication in brain tumor patients, significantly impacting quality of life.
• Tumoral epilepsy management is complex, requiring tailored therapeutic strategies.
• Surgical intervention is a primary option for refractory epilepsy associated with brain tumors.

Purpose of the Study:

• To review the role of surgery in managing drug-resistant epilepsy in brain tumor patients.
• To discuss the selection criteria for epilepsy surgery in the context of brain tumor pathology and oncologic goals.
• To analyze the balance between seizure control and the risk of postoperative deficits.

Main Methods:

• Review of clinical and imaging data (MRI) to predict tumor pathology and malignant potential.
• Evaluation of surgical candidacy based on tumor characteristics, location, and potential for gross total resection.
• Consideration of epileptologic outcomes versus oncologic imperatives in surgical decision-making.

Main Results:

• Gross total resection in tumoral epilepsy can lead to high rates of postoperative seizure freedom.
• Glioneuronal tumors often benefit from epilepsy surgery, but location within eloquent cortex poses risks.
• For low-grade gliomas and aggressive neoplasms, surgical resection is primarily driven by oncologic outcomes, correlating with survival and seizure control.

Conclusions:

• Epilepsy surgery is a vital treatment for refractory tumoral epilepsy, with outcomes dependent on careful patient and tumor selection.
• Balancing the benefits of seizure control against the risks of neurological deficits is paramount, especially in eloquent brain regions.
• Surgical strategy must integrate both epileptologic and oncologic considerations for optimal patient management.